Posted by Michael Wonder on 20 Aug 2018
PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible
20 August 2018 - Vertex Pharmaceuticals announces that it has received the PBAC recommendation for Orkambi (lumacaftor/ivacaftor) to be listed on the PBS in Australia for people ages six and over with cystic fibrosis who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
“We’re very pleased that lumacaftor/ivacaftor received a positive PBAC recommendation for cystic fibrosis patients in Australia, which brings those who have long been waiting closer to receiving this important medicine,” said Simon Bedson, International General Manager at Vertex. “We welcome the PBAC decision and are now working with the Australian Government to finalise the agreement as quickly as possible to make lumacaftor/ivacaftor available to patients.”
Many thousands of patients worldwide are already receiving lumacaftor/ivacaftor in countries where it is reimbursed including Austria, Denmark, Germany, Ireland, Italy, Sweden, the Netherlands and the U.S.
